Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL

Clinical trial NCT00603668 · COMPLETED

Trial details

NCT number: NCT00603668
Sponsor: Gilead Sciences
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Chronic Lymphocytic Lymphoma

Start date: 2008-08-01
Primary completion: 2013-01-01
Enrollment: 19

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.